Cancer Research Institute in the Catholic University of Korea, Seoul 137-701, Korea.
Cancer Research Institute in the Catholic University of Korea, Seoul 137-701, Korea. ; Division of Hematology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 137-701, Korea.
Immune Netw. 2014 Dec;14(6):296-306. doi: 10.4110/in.2014.14.6.296. Epub 2014 Dec 22.
There is growing evidence that crosstalk between mantle cell lymphoma (MCL) cells and stromal microenvironments, such as bone marrow and secondary lymphoid tissues, promotes tumor progression by enhancing survival and growth as well as drug resistance of MCL cells. Recent advances in the understanding of lymphoma microenvironment have led to the identification of crucial factors involved in the crosstalk and subsequent generation of their targeted agents. In the present study, we evaluated the combinatory effect of blocking antibodies (Ab) targeting CXCR4 and VLA-4, both of which were known to play significant roles in the induction of environment-mediated drug resistance (EMDR) in MCL cell line, Jeko-1. Simultaneous treatment with anti-CXCR4 and anti-VLA-4 Ab not only reduced the migration of Jeko-1 cells into the protective stromal cells, but also enhanced sensitivity of Jeko-1 to a chemotherapeutic agent to a greater degree than with either Ab alone. These combinatorial effects were associated with decreased phosphorylation of ERK1/2, AKT and NF-κB. Importantly, drug resistance could not be overcome once the adhesion of Jeko-1 to the stromal occurred despite the combined use of Abs, suggesting that the efforts to mitigate migration of MCLs should be attempted as much as possible. Our results provide a basis for a future development of therapeutic strategies targeting both CXCR4 and VLA-4, such as Ab combinations or bispecific antibodies, to improve treatment outcomes of MCL with grave prognosis.
越来越多的证据表明,套细胞淋巴瘤(MCL)细胞与基质微环境(如骨髓和次级淋巴组织)之间的串扰通过增强 MCL 细胞的存活和生长以及耐药性来促进肿瘤进展。对淋巴瘤微环境的理解的最新进展导致确定了参与串扰和随后产生其靶向剂的关键因素。在本研究中,我们评估了靶向 CXCR4 和 VLA-4 的阻断抗体(Ab)的组合效应,这两者都已知在诱导 MCL 细胞系 Jeko-1 中的环境介导的耐药性(EMDR)中发挥重要作用。同时用抗 CXCR4 和抗 VLA-4 Ab 处理不仅减少了 Jeko-1 细胞向保护性基质细胞的迁移,而且使 Jeko-1 对化疗药物的敏感性增强程度大于单独使用任何一种 Ab。这些组合效应与 ERK1/2、AKT 和 NF-κB 的磷酸化减少有关。重要的是,一旦 Jeko-1 与基质细胞发生黏附,就不能克服耐药性,尽管联合使用 Abs,这表明应尽可能尝试减轻 MCL 迁移的努力。我们的结果为未来开发针对 CXCR4 和 VLA-4 的治疗策略提供了基础,例如 Ab 联合或双特异性抗体,以改善预后不良的 MCL 的治疗效果。